CLINICAL_TRIALS
trial_result
· 2022-09-21
Clinical Trial Update: Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) [Phase 3]
Summary
TRuE-V2, a Phase 3 trial evaluating topical ruxolitinib (Opzelura) for non-segmental vitiligo, completed with results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Incyte Corporation | Conditions: Non-segmental Vitiligo | Phase 3 | Status: COMPLETED | Results posted: 2022-09-21